University of Texas, Arlington NURS 5334/NURS5334: Quiz 2
and Answers (explained) | 100% correct 2025/26 EXAM with
Questions and Answers/Plus a Rationale Updated 2026
A+/Instant Download PDF
EXAM COVERAGE
1. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion Principles
2. Pharmacodynamics: Receptor Theory, Agonists, Antagonists, and Dose-Response Relationships
3. Pharmacogenetics, Adverse Drug Reactions, and Medication Safety Across Lifespans
4. Autonomic Nervous System Pharmacology: Cholinergic and Adrenergic Agonists/Antagonists
5. Cardiovascular Pharmacotherapy: Management of Hypertension, Heart Failure, and Angina
6. Renal Pharmacology: Diuretics, Fluid Balance, and Electrolyte Regulation
7. Central Nervous System Pharmacology: Sedatives, Anxiolytics, and Antidepressant Agents
8. Endocrine Pharmacology: Management of Diabetes Mellitus and Thyroid Disorders
9. Antimicrobial Principles and Pharmacological Management of Common Infections
1. A patient with severe chronic kidney disease (Stage 4) is prescribed a medication that is
primarily eliminated unchanged by the kidneys. What adjustment does the nurse practitioner
anticipate regarding the dosing regimen to avoid toxicity?
A. Increase the individual dose while keeping the dosing interval standard
B. Decrease the individual dose or lengthen the dosing interval
C. Administer the drug exclusively via the intramuscular route
, D. Double the loading dose to compensate for renal impairment
CORRECT ANSWER : B
Rationale: In advanced renal failure, drug clearance is significantly reduced, which causes
accumulation and toxicity if standard dosing is maintained. To prevent toxic drug levels,
clinicians must either reduce individual maintenance doses or extend the dosing interval based
on creatinine clearance.
2. A drug has a fixed half-life of 24 hours. Assuming repeated, consistent dosing at fixed intervals,
approximately how long will it take for the drug to achieve steady-state plasma concentrations?
A. 24 hours
B. 48 hours
C. 120 hours
D. 240 hours
CORRECT ANSWER : C
Rationale: Steady-state plasma concentration is reliably achieved after approximately 4 to 5
half-lives of a drug administered at regular intervals. Multiplying a 24-hour half-life by 5 yields
120 hours, representing the time required for intake and elimination rates to balance.
3. A patient is prescribed a medication that exhibits 95% plasma protein binding. Which scenario
best explains the potential clinical implication of this pharmacokinetic property when a second
highly protein-bound drug is introduced?
A. The drug will be instantly cleared through glomerular filtration without hepatic alteration.
B. Displacement of the first drug by the second agent can increase free, active drug
concentrations, temporarily raising toxicity risk.
C. Protein binding prevents the drug from ever reaching therapeutic tissue receptors.
D. The drug's volume of distribution will expand infinitely across all body fluid compartments.
CORRECT ANSWER : B
Rationale: Highly protein-bound drugs circulate predominantly attached to albumin. If another
drug with higher affinity displaces it, the abrupt increase in free (unbound) active drug
molecules can trigger sudden pharmacological toxicity.
, 4. Why are neonates and infants at significantly greater risk for exaggerated pharmacological
responses and toxicity from drugs that are highly protein-bound?
A. Neonates possess accelerated renal blood flow and hyper-filtration capacity.
B. Neonates have lower plasma protein concentrations and decreased binding affinity,
increasing the fraction of free, active drug.
C. Neonates lack hepatic enzymes entirely, preventing any drug metabolism.
D. Neonates have an immature blood-brain barrier that blocks all lipid-soluble compounds.
CORRECT ANSWER : B
Rationale: Neonates have lower absolute concentrations of plasma proteins (like albumin) and
lower binding capacity. This leaves a much higher percentage of circulating drug unbound
(free), magnifying therapeutic and toxic tissue effects.
5. At approximately what age in a pediatric patient are adult levels of renal clearance and
glomerular filtration rate achieved?
A. 1 month
B. 3 months
C. 12 months
D. 36 months
CORRECT ANSWER : C
Rationale: Glomerular filtration rate is low at birth but rises rapidly during the first weeks of
life, reaching adult functional capacity by approximately 12 months of age. This maturation
trajectory dictates pediatric dosing adjustments for renally eliminated medications.
6. A medication is noted to have a very low volume of distribution ($V_d$) of approximately 0.07
L/kg. How should the nurse practitioner interpret this pharmacokinetic value?
A. The drug is highly lipophilic and sequesters extensively within adipose tissue stores.
B. The drug is largely confined to the vascular compartment, often due to high plasma
protein binding or large molecular size.
C. The drug rapidly crosses cell membranes and distributes equally across all body water spaces.
D. The drug undergoes rapid first-pass hepatic elimination before systemic circulation.
and Answers (explained) | 100% correct 2025/26 EXAM with
Questions and Answers/Plus a Rationale Updated 2026
A+/Instant Download PDF
EXAM COVERAGE
1. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion Principles
2. Pharmacodynamics: Receptor Theory, Agonists, Antagonists, and Dose-Response Relationships
3. Pharmacogenetics, Adverse Drug Reactions, and Medication Safety Across Lifespans
4. Autonomic Nervous System Pharmacology: Cholinergic and Adrenergic Agonists/Antagonists
5. Cardiovascular Pharmacotherapy: Management of Hypertension, Heart Failure, and Angina
6. Renal Pharmacology: Diuretics, Fluid Balance, and Electrolyte Regulation
7. Central Nervous System Pharmacology: Sedatives, Anxiolytics, and Antidepressant Agents
8. Endocrine Pharmacology: Management of Diabetes Mellitus and Thyroid Disorders
9. Antimicrobial Principles and Pharmacological Management of Common Infections
1. A patient with severe chronic kidney disease (Stage 4) is prescribed a medication that is
primarily eliminated unchanged by the kidneys. What adjustment does the nurse practitioner
anticipate regarding the dosing regimen to avoid toxicity?
A. Increase the individual dose while keeping the dosing interval standard
B. Decrease the individual dose or lengthen the dosing interval
C. Administer the drug exclusively via the intramuscular route
, D. Double the loading dose to compensate for renal impairment
CORRECT ANSWER : B
Rationale: In advanced renal failure, drug clearance is significantly reduced, which causes
accumulation and toxicity if standard dosing is maintained. To prevent toxic drug levels,
clinicians must either reduce individual maintenance doses or extend the dosing interval based
on creatinine clearance.
2. A drug has a fixed half-life of 24 hours. Assuming repeated, consistent dosing at fixed intervals,
approximately how long will it take for the drug to achieve steady-state plasma concentrations?
A. 24 hours
B. 48 hours
C. 120 hours
D. 240 hours
CORRECT ANSWER : C
Rationale: Steady-state plasma concentration is reliably achieved after approximately 4 to 5
half-lives of a drug administered at regular intervals. Multiplying a 24-hour half-life by 5 yields
120 hours, representing the time required for intake and elimination rates to balance.
3. A patient is prescribed a medication that exhibits 95% plasma protein binding. Which scenario
best explains the potential clinical implication of this pharmacokinetic property when a second
highly protein-bound drug is introduced?
A. The drug will be instantly cleared through glomerular filtration without hepatic alteration.
B. Displacement of the first drug by the second agent can increase free, active drug
concentrations, temporarily raising toxicity risk.
C. Protein binding prevents the drug from ever reaching therapeutic tissue receptors.
D. The drug's volume of distribution will expand infinitely across all body fluid compartments.
CORRECT ANSWER : B
Rationale: Highly protein-bound drugs circulate predominantly attached to albumin. If another
drug with higher affinity displaces it, the abrupt increase in free (unbound) active drug
molecules can trigger sudden pharmacological toxicity.
, 4. Why are neonates and infants at significantly greater risk for exaggerated pharmacological
responses and toxicity from drugs that are highly protein-bound?
A. Neonates possess accelerated renal blood flow and hyper-filtration capacity.
B. Neonates have lower plasma protein concentrations and decreased binding affinity,
increasing the fraction of free, active drug.
C. Neonates lack hepatic enzymes entirely, preventing any drug metabolism.
D. Neonates have an immature blood-brain barrier that blocks all lipid-soluble compounds.
CORRECT ANSWER : B
Rationale: Neonates have lower absolute concentrations of plasma proteins (like albumin) and
lower binding capacity. This leaves a much higher percentage of circulating drug unbound
(free), magnifying therapeutic and toxic tissue effects.
5. At approximately what age in a pediatric patient are adult levels of renal clearance and
glomerular filtration rate achieved?
A. 1 month
B. 3 months
C. 12 months
D. 36 months
CORRECT ANSWER : C
Rationale: Glomerular filtration rate is low at birth but rises rapidly during the first weeks of
life, reaching adult functional capacity by approximately 12 months of age. This maturation
trajectory dictates pediatric dosing adjustments for renally eliminated medications.
6. A medication is noted to have a very low volume of distribution ($V_d$) of approximately 0.07
L/kg. How should the nurse practitioner interpret this pharmacokinetic value?
A. The drug is highly lipophilic and sequesters extensively within adipose tissue stores.
B. The drug is largely confined to the vascular compartment, often due to high plasma
protein binding or large molecular size.
C. The drug rapidly crosses cell membranes and distributes equally across all body water spaces.
D. The drug undergoes rapid first-pass hepatic elimination before systemic circulation.
